LLY RSI

What is LLY?

Eli Lilly and Company was founded back in 1876 by Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist who wanted to improve the quality of medicine. Headquartered in Indianapolis, the company has evolved from a small laboratory into one of the most valuable healthcare entities in the world. Their core business model revolves around intense research and development, focusing on discovering and manufacturing medicines that address some of the world's most significant health challenges.

The company’s product portfolio is currently dominated by its leadership in metabolic health. While they were the first to commercially produce insulin in the 1920s, they have recently shifted the landscape with tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management. These drugs have become massive revenue drivers. Beyond metabolic health, Lilly has a strong presence in oncology with Verzenio and is making significant strides in neuroscience with Donanemab, a treatment targeting Alzheimer’s disease.

Historically, Lilly has been a pioneer in industrial-scale manufacturing. They were instrumental in mass-producing the Salk polio vaccine and were early leaders in the production of penicillin. This legacy of scaling complex biologicals continues today as they invest billions into new manufacturing sites to meet the insatiable global demand for their GLP-1 receptor agonists.

Financially, Lilly is in a league of its own, boasting a market capitalization that has recently surpassed most of its traditional peers. Revenue growth is currently fueled by the rapid adoption of their new blockbuster drugs, providing the capital necessary to reinvest nearly 25% of sales back into R&D.

Looking ahead to 2026, the strategic outlook is centered on supply chain dominance and pipeline diversification. By 2026, many of their new production facilities will be fully operational, alleviating current supply constraints. Expect them to push further into oral versions of metabolic drugs and expand their immunology portfolio. With a robust balance sheet and a commanding lead in the obesity market, Lilly is positioned to remain a cornerstone of the healthcare sector for the foreseeable future.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For LLY, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Eli Lilly & Co. is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding LLY RSI Signals

• Oversold (RSI below 30): When LLY RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates LLY may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When LLY price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for LLY

This page displays both daily and weekly RSI for LLY. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Eli Lilly & Co.'s momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when LLY RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Eli Lilly & Co. has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.